blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3131566

EP3131566 - BI-TERMINAL PEGYLATED INTEGRIN-BINDING PEPTIDES AND METHODS OF USE THEREOF [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  11.08.2023
Database last updated on 19.07.2024
FormerThe patent has been granted
Status updated on  02.09.2022
FormerGrant of patent is intended
Status updated on  25.04.2022
FormerExamination is in progress
Status updated on  14.08.2019
FormerRequest for examination was made
Status updated on  20.01.2017
FormerThe international publication has been made
Status updated on  07.11.2016
Most recent event   Tooltip19.04.2024Lapse of the patent in a contracting state
New state(s): IE		published on 22.05.2024  [2024/21]
Applicant(s)For all designated states
The Regents of the University of California
Office of Technology Transfer
1111 Franklin Street, 5th Floor
Oakland, CA 94607 / US
[2017/08]
Inventor(s)01 / HAUSNER, Sven H.
The Regents of the University of California
1111 Franklin St.
12th Floor
Oakland, California 94607 / US
02 / SUTCLIFFE, Julie L.
The Regents of the University of California
1111 Franklin St.
12th Floor
Oakland, California 94607 / US
 [2017/08]
Representative(s)J A Kemp LLP
80 Turnmill Street
London EC1M 5QU / GB
[2022/40]
Former [2017/08]Campbell, Patrick John Henry
J A Kemp
14 South Square
Gray's Inn
London WC1R 5JJ / GB
Application number, filing date15779171.614.04.2015
[2017/08]
WO2015US25700
Priority number, dateUS201461979997P15.04.2014         Original published format: US 201461979997 P
[2017/08]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2015160770
Date:22.10.2015
Language:EN
[2015/42]
Type: A1 Application with search report 
No.:EP3131566
Date:22.02.2017
Language:EN
The application published by WIPO in one of the EPO official languages on 22.10.2015 takes the place of the publication of the European patent application.
[2017/08]
Type: B1 Patent specification 
No.:EP3131566
Date:05.10.2022
Language:EN
[2022/40]
Search report(s)International search report - published on:US22.10.2015
(Supplementary) European search report - dispatched on:EP06.10.2017
ClassificationIPC:A61K38/00, A61K39/385, C07K7/06, C07K14/705, C07K14/085
[2017/45]
CPC:
C07K7/06 (EP,US); A61K31/337 (EP,US); A61K38/00 (EP,US);
A61K47/60 (EP,US); A61K47/64 (EP,US); A61K51/082 (US);
C07K14/70546 (EP,US); C12N2770/32122 (EP,US) (-)
Former IPC [2017/08]A61K38/00, A61K39/385, C07K7/06
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/08]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
TitleGerman:BI-TERMINALE PEGYLIERTE INTEGRINBINDENDE PEPTIDE UND VERFAHREN ZUR VERWENDUNG DAVON[2017/08]
English:BI-TERMINAL PEGYLATED INTEGRIN-BINDING PEPTIDES AND METHODS OF USE THEREOF[2017/08]
French:PEPTIDES DE LIAISON A L'INTEGRINE PEGYLES AUX DEUX EXTREMITES TERMINALES ET LEURS PROCEDES D'UTILISATION[2022/16]
Former [2017/08]PEPTIDES DE LIAISON A L'INTEGRINE PEGYLES AUX DEUX EXTREMITES TERMINALESLEURS PROCEDES D'UTILISATION
Entry into regional phase07.11.2016National basic fee paid 
07.11.2016Search fee paid 
07.11.2016Designation fee(s) paid 
07.11.2016Examination fee paid 
Examination procedure07.11.2016Examination requested  [2017/08]
07.11.2016Date on which the examining division has become responsible
30.04.2018Amendment by applicant (claims and/or description)
20.08.2019Despatch of a communication from the examining division (Time limit: M06)
26.02.2020Reply to a communication from the examining division
26.04.2022Communication of intention to grant the patent
24.08.2022Fee for grant paid
24.08.2022Fee for publishing/printing paid
24.08.2022Receipt of the translation of the claim(s)
Opposition(s)06.07.2023No opposition filed within time limit [2023/37]
Fees paidRenewal fee
27.04.2017Renewal fee patent year 03
27.04.2018Renewal fee patent year 04
29.04.2019Renewal fee patent year 05
27.04.2020Renewal fee patent year 06
27.04.2021Renewal fee patent year 07
27.04.2022Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL05.10.2022
AT05.10.2022
CZ05.10.2022
DK05.10.2022
EE05.10.2022
FI05.10.2022
HR05.10.2022
LT05.10.2022
LV05.10.2022
MC05.10.2022
PL05.10.2022
RO05.10.2022
RS05.10.2022
SE05.10.2022
SI05.10.2022
SK05.10.2022
SM05.10.2022
NO05.01.2023
GR06.01.2023
IS05.02.2023
PT06.02.2023
IE14.04.2023
LU14.04.2023
[2024/21]
Former [2024/08]AL05.10.2022
AT05.10.2022
CZ05.10.2022
DK05.10.2022
EE05.10.2022
FI05.10.2022
HR05.10.2022
LT05.10.2022
LV05.10.2022
MC05.10.2022
PL05.10.2022
RO05.10.2022
RS05.10.2022
SE05.10.2022
SI05.10.2022
SK05.10.2022
SM05.10.2022
NO05.01.2023
GR06.01.2023
IS05.02.2023
PT06.02.2023
LU14.04.2023
Former [2024/04]AL05.10.2022
AT05.10.2022
CZ05.10.2022
DK05.10.2022
EE05.10.2022
FI05.10.2022
HR05.10.2022
LT05.10.2022
LV05.10.2022
PL05.10.2022
RO05.10.2022
RS05.10.2022
SE05.10.2022
SI05.10.2022
SK05.10.2022
SM05.10.2022
NO05.01.2023
GR06.01.2023
IS05.02.2023
PT06.02.2023
LU14.04.2023
Former [2023/51]AL05.10.2022
AT05.10.2022
CZ05.10.2022
DK05.10.2022
EE05.10.2022
FI05.10.2022
HR05.10.2022
LT05.10.2022
LV05.10.2022
PL05.10.2022
RO05.10.2022
RS05.10.2022
SE05.10.2022
SI05.10.2022
SK05.10.2022
SM05.10.2022
NO05.01.2023
GR06.01.2023
IS05.02.2023
PT06.02.2023
Former [2023/38]AL05.10.2022
AT05.10.2022
CZ05.10.2022
DK05.10.2022
EE05.10.2022
FI05.10.2022
HR05.10.2022
LT05.10.2022
LV05.10.2022
PL05.10.2022
RO05.10.2022
RS05.10.2022
SE05.10.2022
SK05.10.2022
SM05.10.2022
NO05.01.2023
GR06.01.2023
IS05.02.2023
PT06.02.2023
Former [2023/37]AL05.10.2022
AT05.10.2022
CZ05.10.2022
DK05.10.2022
EE05.10.2022
FI05.10.2022
HR05.10.2022
LT05.10.2022
LV05.10.2022
PL05.10.2022
RO05.10.2022
RS05.10.2022
SE05.10.2022
SM05.10.2022
NO05.01.2023
GR06.01.2023
IS05.02.2023
PT06.02.2023
Former [2023/35]AT05.10.2022
CZ05.10.2022
DK05.10.2022
EE05.10.2022
FI05.10.2022
HR05.10.2022
LT05.10.2022
LV05.10.2022
PL05.10.2022
RO05.10.2022
RS05.10.2022
SE05.10.2022
SM05.10.2022
NO05.01.2023
GR06.01.2023
IS05.02.2023
PT06.02.2023
Former [2023/34]AT05.10.2022
DK05.10.2022
EE05.10.2022
FI05.10.2022
HR05.10.2022
LT05.10.2022
LV05.10.2022
PL05.10.2022
RS05.10.2022
SE05.10.2022
SM05.10.2022
NO05.01.2023
GR06.01.2023
IS05.02.2023
PT06.02.2023
Former [2023/33]AT05.10.2022
DK05.10.2022
FI05.10.2022
HR05.10.2022
LT05.10.2022
LV05.10.2022
PL05.10.2022
RS05.10.2022
SE05.10.2022
SM05.10.2022
NO05.01.2023
GR06.01.2023
IS05.02.2023
PT06.02.2023
Former [2023/26]AT05.10.2022
FI05.10.2022
HR05.10.2022
LT05.10.2022
LV05.10.2022
PL05.10.2022
RS05.10.2022
SE05.10.2022
NO05.01.2023
GR06.01.2023
IS05.02.2023
PT06.02.2023
Former [2023/24]AT05.10.2022
FI05.10.2022
HR05.10.2022
LT05.10.2022
LV05.10.2022
SE05.10.2022
NO05.01.2023
GR06.01.2023
PT06.02.2023
Former [2023/23]AT05.10.2022
FI05.10.2022
LT05.10.2022
LV05.10.2022
SE05.10.2022
NO05.01.2023
GR06.01.2023
PT06.02.2023
Former [2023/22]AT05.10.2022
FI05.10.2022
LT05.10.2022
SE05.10.2022
NO05.01.2023
PT06.02.2023
Former [2023/20]LT05.10.2022
NO05.01.2023
Documents cited:Search[IA]WO02087497  (UNIV TEXAS [US]) [I] 1,5-13 * p. 5, line 30 - p. 14, line 15, Fig. 2 * [A] 2-4,14,15;
 [XAI]  - TAPAS K. PAIRA ET AL, "Fluorescent Amphiphilic PEG-Peptide-PEG Triblock Conjugate Micelles for Cell Imaging : Fluorescent Amphiphilic PEG-Peptide-PEG Triblock Conjugate Micelles?...", MACROMOLECULAR BIOSCIENCE, DE, (20140331), vol. 14, no. 7, doi:10.1002/mabi.201400083, ISSN 1616-5187, pages 929 - 935, XP055410234 [X] 1,5-7,9,10 * the whole document * [A] 2-4,14,15 [I] 8,11-13

DOI:   http://dx.doi.org/10.1002/mabi.201400083
 [IA]  - MILLER J S ET AL, "Bioactive hydrogels made from step-growth derived PEG-peptide macromers", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 31, no. 13, doi:10.1016/J.BIOMATERIALS.2010.01.058, ISSN 0142-9612, (20100501), pages 3736 - 3743, (20100206), XP026946011 [I] 1,5-13 * the whole document * [A] 2-4,14,15

DOI:   http://dx.doi.org/10.1016/j.biomaterials.2010.01.058
 [IA]  - WILLIAM J KING ET AL, "Facile formation of dynamic hydrogel microspheres for triggered growth factor delivery", ACTA BIOMATERIALIA, ELSEVIER, AMSTERDAM, NL, vol. 7, no. 3, doi:10.1016/J.ACTBIO.2010.10.026, ISSN 1742-7061, (20101022), pages 975 - 985, (20101026), XP028131189 [I] 1,5-13 * the whole document * [A] 2-4,14,15

DOI:   http://dx.doi.org/10.1016/j.actbio.2010.10.026
 [IA]  - IAN W. HAMLEY, "PEG-Peptide Conjugates", BIOMACROMOLECULES, (20140401), vol. 15, no. 5, doi:10.1021/bm500246w, ISSN 1525-7797, pages 1543 - 1559, XP055231868 [I] 1,5-13 * the whole document * [A] 2-4,14,15

DOI:   http://dx.doi.org/10.1021/bm500246w
 [A]  - S. H. HAUSNER ET AL, "Targeted In vivo Imaging of Integrin v 6 with an Improved Radiotracer and Its Relevance in a Pancreatic Tumor Model", CANCER RESEARCH, US, (20090623), vol. 69, no. 14, doi:10.1158/0008-5472.CAN-08-4410, ISSN 0008-5472, pages 5843 - 5850, XP055231867 [A] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1158/0008-5472.CAN-08-4410
 [A]  - I. D. CAMPBELL ET AL, "Integrin Structure, Activation, and Interactions", COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY, (20110119), vol. 3, no. 3, doi:10.1101/cshperspect.a004994, pages a004994 - a004994, XP055410758 [A] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1101/cshperspect.a004994
International search[A]US6110466  (LOMONOSSOFF GEORGE PETER [GB], et al) [A] 8 * ; figure 5b; column 5, lines 23-25; column 25 *;
 [YA]  - HAUSNER, SH et al., "Targeted In Vivo Imaging Of Integrin alpha(sub)(v)(Beta)6 With An Improved Radiotracer And Its Relevance In A Pancreatic Tumor Model.", Cancer Research, (20090715), vol. 69, no. 14, pages 5843 - 5850, XP055231867 [Y] 1-7, 9 * ; abstract; page 2, second paragraph; page 6, sixth paragraph. DOI: 10.1158/0008-5472.CAN-08-4410. * [A] 8

DOI:   http://dx.doi.org/10.1158/0008-5472.CAN-08-4410
 [Y]  - HAMLEY, IW., "PEG-Peptide Conjugates.", Biomacromolecules, (20140401), vol. 15, pages 1543 - 1559, XP055231868 [Y] 1-7, 9 * ; page 1545, first column, fifth paragraph. DOI: 10.1021/bm500246w. *

DOI:   http://dx.doi.org/10.1021/bm500246w
 [A]  - HAUSNER, SH et al., "Use Of A Peptide Derived From Foot-And-Mouth Disease Virus For The Noninvasive Imaging Of Human Cancer: Generation And Evaluation Of 4-[18F]Fluorobenzoyl A20FMDV2 For In Vivo Imaging Of Integrin alpha(v)(Beta)6 Expression With Positron Emission Tomography", Cancer Research, (20070815), vol. 67, no. 16, pages 7833 - 7840, XP002630513 [A] 8 * ; abstract. DOI: 10.1158/0008-5472.CAN-07-1026. *

DOI:   http://dx.doi.org/10.1158/0008-5472.CAN-07-1026
Examination   - KRAFT E A, "Definition of an unexpected ligand recognition motif for alpha3ß6 integrin", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, (19990122), vol. 274, no. 4, doi:10.1074/JBC.274.4.1979, ISSN 0021-9258, pages 1979 - 1985, XP002136307

DOI:   http://dx.doi.org/10.1074/jbc.274.4.1979
    - S. H. HAUSNER ET AL, "The Effect of Bi-Terminal PEGylation of an Integrin v 6-Targeted 18F Peptide on Pharmacokinetics and Tumor Uptake", THE JOURNAL OF NUCLEAR MEDICINE, US, (20150501), vol. 56, no. 5, doi:10.2967/jnumed.114.150680, ISSN 0161-5505, pages 784 - 790, XP055612706

DOI:   http://dx.doi.org/10.2967/jnumed.114.150680
by applicantWO9500534
 US5429133
 WO9606641
 WO0232404
 US6403374
 US6800733
 WO2005010816
 WO2005116226
 US7157566
 WO2007039728
 US2013164369
    - HAUSNER et al., Cancer Res, (20090000), vol. 69, pages 5843 - 50
    - LIU et al., Anal. Biochem., (20010000), vol. 295, pages 9 - 16
    - MILLER et al., Drug Dev. Res., (19950000), vol. 35, pages 20 - 32
    - PACE et al., Biophysical J., (19980000), vol. 75, pages 422 - 427
    - BREUSS et al., J. Cell Sci., (19950000), vol. 108, pages 2241 - 2251
    - CLARK et al., Am. J. Path., (19960000), vol. 148, pages 1407 - 1421
    - TARN et al., Protein Sci., (19980000), vol. 7, pages 1583 - 1592
    - ROMANOVSKIS et al., J. Pept . Res., (19980000), vol. 52, pages 356 - 374
    - CAMARERO et al., J. Amer. Chem. Soc., (19990000), vol. 121, pages 5597 - 5598
    - VALERO et al., J. Pept. Res., (19990000), vol. 53, no. 1, pages 56 - 67
    - GLEITER, Adv. Mater., (19920000), vol. 4, pages 474 - 481
    - BRUCHER et al., Science, (19980000), vol. 281, pages 2016 - 2018
    - MATTOUSI et al., J. Am. Chem. Soc., (20000000), vol. 122, pages 12142 - 12150
    - ALIVISATOS, Pure Appl . Chem., (20000000), vol. 72, pages 3 - 9
    - BURROWS et al., P.N.A.S. USA, (19930000), vol. 90, pages 8996 - 9000
    - RAN et al., Cancer Res., (19980000), vol. 58, pages 4646 - 4653
    - HUANG et al., Science, (19970000), vol. 275, pages 547 - 550
    - TSAI et al., Dis. Colon Rectum, (19950000), vol. 38, pages 1067 - 1074
    - AIELLO et al., P.N.A.S. USA, (19950000), vol. 92, pages 10457 - 10461
    - DOAN et al., Mol. Microbiol., (20050000), vol. 55, pages 1767 - 1781
    - CRAMERI et al., Nat. Biotechnol., (19960000), vol. 14, pages 315 - 319
    - SHANER et al., Nat. Biotechnol., (20040000), vol. 22, pages 1567 - 1572
    - TSIEN, Annu. Rev. Biochem., (19980000), vol. 67, page 509
    - NAGAL et al., Nat. Biotechnol., (20020000), vol. 20, pages 87 - 90
    - WANG et al., Proc. Natl. Acad. Sci. U.S.A., (20040000), vol. 101, pages 16745 - 16749
    - FISCHER et al., FEBS Lett., (20040000), vol. 577, pages 227 - 232
    - FISCHER et al., FEBS Lett., (20060000), vol. 580, pages 2495 - 2502
    - ANDERSSON-ENGELS et al., Phys. Med. Biol., (19970000), vol. 42, pages 815 - 824
    - FRANGIONI, Curr. Opin. Chem. Biol., (20030000), vol. 7, pages 626 - 634
    - RAMANUJAM et al., IEEE Transactions on Biomedical Engineering, (20010000), vol. 48, pages 1034 - 1041
    - JACKSON et al., Virus Res., (20030000), vol. 91, pages 33 - 46
    - LOGAN et al., Nature, (19930000), vol. 362, pages 566 - 8
    - ROBERTS et al., Adv. Drug Deliver. Rev., (20020000), vol. 54, pages 459 - 76
    - KNOP et al., Angewandte Chemie, (20100000), vol. 49, pages 6288 - 308
    - HYNES, Cell, (20020000), vol. 110, pages 673 - 87
    - BANDYOPADHYAY et al., "Defining the role of integrin alphavbeta6 in cancer", Current drug targets, (20090000), vol. 10, no. 7, doi:10.2174/138945009788680374, pages 645 - 52, XP009170853

DOI:   http://dx.doi.org/10.2174/138945009788680374
    - HAUSNER et al., Cancer Res., (20070000), vol. 67, pages 7833 - 40
    - BATES, Cell Cycle, (20050000), vol. 4, pages 1350 - 2
    - HAZELBAG et al., J Pathol., (20070000), vol. 212, pages 316 - 24
    - ZHANG et al., Clin Oncol-UK, (20080000), vol. 20, pages 61 - 6
    - HAUSNER et al., Cancer Res., (20090000), vol. 69, pages 5843 - 50
    - KIMURA et al., Clin Cancer Res., (20120000), vol. 18, pages 839 - 49
    - BRIAND et al., Proc Natl Acad Sci USA, (19970000), vol. 94, pages 12545 - 50
    - FLETCHER et al., Chem Rev., (19980000), vol. 98, pages 763 - 95
    - FISCHER, Curr Protein Pept Sc., (20030000), vol. 4, pages 339 - 56
    - SUTCLIFFE-GOULDEN et al., Bioorg Med Chem Lett., (20000000), vol. 10, pages 1501 - 3
    - SUTCLIFFE-GOULDEN et al., Eur J Nucl Med Mol /., (20020000), vol. 29, pages 754 - 9
    - HAUSNER et al., J Med Chem., (20080000), vol. 51, pages 5901 - 4
    - REILLY et al., J. Nuclear Medicine, (20000000), vol. 41, pages 429 - 38
    - AHMED et al., J Histochem Cytochem., (20020000), vol. 50, pages 1371 - 80
    - LIU et al., Head Neck Oncol., (20130000), vol. 5, page 7
    - BANDYOPADHYAY et al., Curr Drug Targets, (20090000), vol. 10, pages 645 - 52
    - SIPOS et al., "Immunohistochemical screening for beta6-integrin subunit expression in adenocarcinomas using a novel monoclonal antibody reveals strong up-regulation in pancreatic ductal adenocarcinomas in vivo and in vitro", Histopathology, (20040000), vol. 45, no. 3, doi:10.1111/j.1365-2559.2004.01919.x, pages 226 - 36, XP002331221

DOI:   http://dx.doi.org/10.1111/j.1365-2559.2004.01919.x
    - SUTCLIFFE-GOULDEN et al., Eur J Nucl Med Mol Imaging, (20020000), vol. 29, pages 754 - 9
    - WHITE et al., Nat Chem., (20110000), vol. 3, pages 509 - 24
    - OKARVI, Med Res Rev., (20040000), vol. 24, pages 357 - 97
    - ROXIN et al., Future Med Chem., (20120000), vol. 4, pages 1601 - 18
    - AHMED et al., "Alpha(v)beta(6) integrin-A marker for the malignant potential of epithelial ovarian cancer", Thejournal of histochemistry and cytochemistry, (20020000), vol. 50, no. 10, pages 1371 - 80
    - ELAYADI et al., "A peptide selected by biopanning identifies the integrin alphavbeta6 as a prognostic biomarker for nonsmall cell lung cancer", Cancer research, (20070000), vol. 67, no. 12, doi:10.1158/0008-5472.CAN-07-0245, pages 5889 - 95, XP055383669

DOI:   http://dx.doi.org/10.1158/0008-5472.CAN-07-0245
    - LIU et al., "Integrin alphavbeta6 as a novel marker for diagnosis and metastatic potential of thyroid carcinoma", Head & neck oncology, (20130000), vol. 5, no. 1, page 7
    - JONES et al., "ADAM 10 is over expressed in oral squamous cell carcinoma and contributes to invasive behaviour through a functional association with alphavbeta6 integrin", FEBS letters, (20130000), vol. 587, no. 21, doi:10.1016/j.febslet.2013.09.010, pages 3529 - 34, XP028743673

DOI:   http://dx.doi.org/10.1016/j.febslet.2013.09.010
    - ZHUANG et al., "Clinical significance of integrin alphavbeta6 expression effects on gastric carcinoma invasiveness and progression via cancer-associated fibroblasts", Medical oncology, (20130000), vol. 30, no. 3, page 580
    - VOGETSEDER et al., "alphav-Integrin isoform expression in primary human tumors and brain metastases", International journal of cancer Journal international du cancer, (20130000), vol. 133, no. 10, doi:10.1002/ijc.28267, pages 2362 - 71, XP055168245

DOI:   http://dx.doi.org/10.1002/ijc.28267
    - AHMED et al., "avP6 Integrin-A Marker for the Malignant Potential of Epithelial Ovarian Cancer", Journal of Histochemistry & Cytochemistry, (20020000), vol. 50, no. 10, doi:10.1177/002215540205001010, pages 1371 - 9, XP055030391

DOI:   http://dx.doi.org/10.1177/002215540205001010
    - AHMED et al., "Association between alphavbeta6 integrin expression, elevated p42/44 kDa MAPK, and plasminogen-dependent matrix degradation in ovarian cancer", Journal of cellular biochemistry, (20020000), vol. 84, no. 4, pages 675 - 86
    - KAWASHIMA et al., "Expression of alphav integrin family in gastric carcinomas: increased alphavbeta6 is associated with lymph node metastasis", Pathology, research and practice, (20030000), vol. 199, no. 2, doi:10.1078/0344-0338-00355, pages 57 - 64, XP004958871

DOI:   http://dx.doi.org/10.1078/0344-0338-00355
    - HSIAO et al., "Cyclic alphavbeta6-targeting peptide selected from biopanning with clinical potential for head and neck squamous cell carcinoma", Head & neck, (20100000), vol. 32, no. 2, pages 160 - 72
    - BATES, "The alphaVbeta6 integrin as a novel molecular target for colorectal cancer", Future oncology, (20050000), vol. 1, no. 6, doi:10.2217/14796694.1.6.821, pages 821 - 8, XP008135017

DOI:   http://dx.doi.org/10.2217/14796694.1.6.821
    - THOMAS et al., "avP6 integrin in wound healing and cancer of the oral cavity", Journal of Oral Pathology & Medicine, (20060000), vol. 35, no. 1, doi:10.1111/j.1600-0714.2005.00374.x, pages 1 - 10, XP008102570

DOI:   http://dx.doi.org/10.1111/j.1600-0714.2005.00374.x
    - ALLEN et al., "Altered Microenvironment Promotes Progression of Preinvasive Breast Cancer: Myoepithelial Expression of alphavbeta6 Integrin in DCIS Identifies High-risk Patients and Predicts Recurrence", Clinical cancer research, (20140000), vol. 20, no. 2, pages 344 - 57
    - PRUDKIN et al., "Epithelial-to-mesenchymal transition in the development and progression of adenocarcinoma and squamous cell carcinoma of the lung", Modern pathology, (20090000), vol. 22, no. 5, pages 668 - 78
    - ANNES et al., "Integrin alphaVbeta6-mediated activation of latent TGF-beta requires the latent TGF-beta binding protein-1", The Journal of cell biology, (20040000), vol. 165, no. 5, pages 723 - 34
    - BATES et al., "Transcriptional activation of integrin beta6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma", The Journal of clinical investigation, (20050000), vol. 115, no. 2, doi:10.1172/JCI23183, pages 339 - 47, XP009170831

DOI:   http://dx.doi.org/10.1172/JCI23183
    - BERGHOFF et al., "Invasion patterns in brain metastases of solid cancers", Neuro-Oncology, (20130000), vol. 15, no. 12, pages 1664 - 72
    - PENG et al., "Integrin alphavbeta6 and transcriptional factor Ets-1 act as prognostic indicators in colorectal cancer", Cell & bioscience, (20140000), vol. 4, no. 1, doi:10.1186/2045-3701-4-53, page 53, XP021198179

DOI:   http://dx.doi.org/10.1186/2045-3701-4-53
    - MOORE et al., "Therapeutic targeting of integrin alphavbeta6 in breast cancer", Journal of the National Cancer Institute, (20140000), vol. 106, no. 8, doi:10.1093/jnci/dju169, XP055157642

DOI:   http://dx.doi.org/10.1093/jnci/dju169
    - BERGHOFF et al., "alphavbeta3, alphavbeta5 and alphavbeta6 integrins in brain metastases of lung cancer", Clinical & experimental metastasis, (20140000), vol. 31, no. 7, pages 841 - 51
    - NIU et al., "Protein expression of eIF4E and integrin alphavbeta6 in colon cancer can predict clinical significance, reveal their correlation and imply possible mechanism of interaction", Cell & bioscience, (20140000), vol. 4, doi:10.1186/2045-3701-4-23, page 23, XP021186977

DOI:   http://dx.doi.org/10.1186/2045-3701-4-23
    - SUN et al., "Interleukin-8 promotes cell migration through integrin alphavbeta6 upregulation in colorectal cancer", Cancer letters, (20140000), vol. 354, no. 2, pages 245 - 53
    - WANG et al., "SDF-1/CXCR4 axis promotes directional migration of colorectal cancer cells through upregulation of integrin alphavbeta6", Carcinogenesis, (20140000), vol. 35, no. 2, pages 282 - 91
    - BATES, "Colorectal cancer progression: integrin alphavbeta6 and the epithelial-mesenchymal transition (EMT", Cell cycle, (20050000), vol. 4, no. 10, doi:10.4161/cc.4.10.2053, pages 1350 - 2, XP009170854

DOI:   http://dx.doi.org/10.4161/cc.4.10.2053
    - NELSON, "DCIS prognostic markers: a few new candidates emerge", Journal of the National Cancer Institute, (20100000), vol. 102, no. 9, pages 588 - 90
    - SIEGEL et al., Cancer statistics, 2014. CA: a cancer journal for clinicians, (20140000), vol. 64, no. 1, pages 9 - 29
    - CHARI, "Detecting early pancreatic cancer: problems and prospects", Seminars in oncology, (20070000), vol. 34, no. 4, pages 284 - 94
    - PELAEZ-LUNA et al., "Resectability of presymptomatic pancreatic cancer and its relationship to onset of diabetes: a retrospective review of CT scans and fasting glucose values prior to diagnosis", The American journal of gastroenterology, (20070000), vol. 102, no. 10, pages 2157 - 63
    - MCGUIRE et al., "Biopanning of phage displayed peptide libraries for the isolation of cell-specific ligands", Methods in molecular biology, (20090000), vol. 504, pages 291 - 321
    - GRAY et al., "From Phage Display to Nanoparticle Delivery: Functionalizing Liposomes with Multivalent Peptides Improves Targeting to a Cancer Biomarker", Bioconjugate Chemistry, (20120000), vol. 24, no. l, pages 85 - 96
    - MIAO et al., "An engineered knottin peptide labeled with 18F for PET imaging of integrin expression", Bioconjug Chem., (20090000), vol. 20, no. 12, pages 2342 - 7
    - HACKEL et al., "18F-fluorobenzoate-labeled cystine knot peptides for PET imaging of integrin alphavbeta6", Journal of nuclear medicine, (20130000), vol. 54, no. 7, pages 1101 - 5
    - GAGNON et al., "High-throughput in vivo screening of targeted molecular imaging agents", Proceedings of the National Academy of Sciences of the United States of America, (20090000), vol. 106, no. 42, pages 17904 - 9
    - GRAY et al., "Combinatorial Peptide libraries: mining for cell-binding peptides", Chemical reviews, (20140000), vol. 114, no. 2, doi:10.1021/cr400166n, pages 1020 - 81, XP055570072

DOI:   http://dx.doi.org/10.1021/cr400166n
    - HAUSNER et al., "Targeted in vivo imaging of integrin alphavbeta6 with an improved radiotracer and its relevance in a pancreatic tumor model", Cancer research, (20090000), vol. 69, no. 14, doi:10.1158/0008-5472.CAN-08-4410, pages 5843 - 50, XP055231867

DOI:   http://dx.doi.org/10.1158/0008-5472.CAN-08-4410
    - HAUSNER et al., "Use of a peptide derived from foot-and-mouth disease virus for the noninvasive imaging of human cancer: generation and evaluation of 4-[18F]fluorobenzoyl A20FMDV2 for in vivo imaging of integrin alphavbeta6 expression with positron emission tomography", Cancer research, (20070000), vol. 67, no. 16, doi:10.1158/0008-5472.CAN-07-1026, pages 7833 - 40, XP002630513

DOI:   http://dx.doi.org/10.1158/0008-5472.CAN-07-1026
    - HAUSNER et al., "In vitro and in vivo evaluation of the effects of aluminum [(l)(8)F]fluoride radiolabeling on an integrin alphavbeta(6)-specific peptide", Nuclear medicine and biology, (20140000), vol. 41, no. 1, doi:10.1016/j.nucmedbio.2013.09.009, pages 43 - 50, XP055409783

DOI:   http://dx.doi.org/10.1016/j.nucmedbio.2013.09.009
    - HAUSNER et al., "Evaluation of an integrin alphavbeta6-specific peptide labeled with [18F]fluorine by copper-free, strain-promoted click chemistry", Nuclear medicine and biology, (20130000), vol. 40, no. 2, doi:10.1016/j.nucmedbio.2012.10.007, pages 233 - 9, XP055409792

DOI:   http://dx.doi.org/10.1016/j.nucmedbio.2012.10.007
    - HAUSNER et al., "Evaluation of [64Cu]Cu-DOTA and [64Cu]Cu-CB-TE2A chelates for targeted positron emission tomography with an alphavbeta6-specific peptide", Molecular imaging, (20090000), vol. 8, no. 2, pages 111 - 21
    - HAUSNER et al., "In vivo positron emission tomography (PET) imaging with an alphavbeta6 specific peptide radiolabeled using 18F-''click'' chemistry: evaluation and comparison with the corresponding 4-[18F]fluorobenzoyl- and 2-[18F]fluoropropionyl-peptides", Journal of medicinal chemistry, (20080000), vol. 51, no. 19, pages 5901 - 4
    - "Molecular Imaging II. Preface", SEMMLER et al., Handbook of experimental pharmacology, (20080000), vol. 185, pages vii - ix
    - LI et al., "64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression", Journal of nuclear medicine, (20070000), vol. 48, no. 7, pages 1162 - 71
    - ZHOU et al., "Radiolabeled Cyclic RGD Peptides as Radiotracers for Imaging Tumors and Thrombosis by SPECT", Theranostics, (20110000), vol. 1, doi:10.7150/thno/v01p0058, pages 58 - 82, XP002758539

DOI:   http://dx.doi.org/10.7150/thno/v01p0058
    - WHITE et al., "Optimization of the solid-phase synthesis of [18F] radiolabeled peptides for positron emission tomography", Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine, (20120000), vol. 70, no. 12, doi:10.1016/j.apradiso.2012.08.003, pages 2720 - 9, XP055409779

DOI:   http://dx.doi.org/10.1016/j.apradiso.2012.08.003
    - DOU et al., "Expression, purification, and characterization of recombinant human serum albumin fusion protein with two human glucagon-like peptide-1 mutants in Pichia pastoris", Protein expression and purification, (20080000), vol. 61, no. 1, doi:10.1016/j.pep.2008.04.012, pages 45 - 9, XP023182965

DOI:   http://dx.doi.org/10.1016/j.pep.2008.04.012
    - SMITH et al., "Prolonged in vivo residence times of antibody fragments associated with albumin", Bioconjug Chem., (20010000), vol. 12, no. 5, doi:10.1021/bc010003g, pages 750 - 6, XP002270731

DOI:   http://dx.doi.org/10.1021/bc010003g
    - NGUYEN et al., "The pharmacokinetics of an albumin-binding Fab (AB.Fab) can be modulated as a function of affinity for albumin", Protein engineering, design & selection : PEDS, (20060000), vol. 19, no. 7, pages 291 - 7
    - DUMELIN et al., "A portable albumin binder from a DNA-encoded chemical library", Angewandte Chemie, (20080000), vol. 47, no. 17, doi:10.1002/anie.200704936, pages 3196 - 201, XP055041941

DOI:   http://dx.doi.org/10.1002/anie.200704936
    - MULLER et al., "DOTA conjugate with an albumin-binding entity enables the first folic acid-targeted 177Lu-radionuclide tumor therapy in mice", Journal of nuclear medicine, (20130000), vol. 54, no. 1, doi:10.2967/jnumed.112.107235, pages 124 - 31, XP055242492

DOI:   http://dx.doi.org/10.2967/jnumed.112.107235
    - FISCHER et al., "Improved PET imaging of tumors in mice using a novel (18) F-folate conjugate with an albumin-binding entity", Molecular imaging and biology, (20130000), vol. 15, no. 6, pages 649 - 54
    - PANG et al., "A free cysteine prolongs the half-life of a homing peptide and improves its tumor-penetrating activity", Journal of controlled release, (20140000), vol. 175, doi:10.1016/j.jconrel.2013.12.006, pages 48 - 53, XP028820799

DOI:   http://dx.doi.org/10.1016/j.jconrel.2013.12.006
    - ELLERBY et al., "Anti-cancer activity of targeted pro-apoptotic peptides", Nature medicine, (19990000), vol. 5, no. 9, doi:10.1038/12469, pages 1032 - 8, XP002929457

DOI:   http://dx.doi.org/10.1038/12469
    - BARBU et al., "An Antimicrobial Peptidomimetic Induces Mucorales Cell Death through Mitochondria-Mediated Apoptosis", PLoS ONE, (20130000), vol. 8, no. 10, page e76981
    - ARAP et al., "Targeting the prostate for destruction through a vascular address", Proceedings of the National Academy of Sciences of the United States of America, (20020000), vol. 99, no. 3, doi:10.1073/pnas.241655998, pages 1527 - 31, XP002366602

DOI:   http://dx.doi.org/10.1073/pnas.241655998
    - FANTIN et al., "A bifunctional targeted peptide that blocks HER-2 tyrosine kinase and disables mitochondrial function in HER-2-positive carcinoma cells", Cancer research, (20050000), vol. 65, no. 15, pages 6891 - 900, XP055140188
    - KARJALAINEN et al., "Targeting neuropilin-1 in human leukemia and lymphoma", Blood, (20110000), vol. 117, no. 3, pages 920 - 7
    - VON HOFF et al., "Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine", New England Journal of Medicine, (20130000), vol. 369, no. 18, doi:10.1056/NEJMoa1304369, pages 1691 - 703, XP055250743

DOI:   http://dx.doi.org/10.1056/NEJMoa1304369
    - FRIEDMAN et al., "The smart targeting of nanoparticles", Current pharmaceutical design, (20130000), vol. 19, no. 35, doi:10.2174/13816128113199990375, pages 6315 - 29, XP055657670

DOI:   http://dx.doi.org/10.2174/13816128113199990375
    - LUO et al., "Well-defined, size-tunable, multifunctional micelles for efficient paclitaxel delivery for cancer treatment", Bioconjug Chem., (20100000), vol. 21, no. 7, doi:10.1021/bc1000033, pages 1216 - 24, XP055196709

DOI:   http://dx.doi.org/10.1021/bc1000033
    - LI et al., "A novel size-tunable nanocarrier system for targeted anticancer drug delivery", Journal of Controlled Release, (20100000), vol. 144, no. 3, doi:10.1016/j.jconrel.2010.02.027, pages 314 - 23, XP055147647

DOI:   http://dx.doi.org/10.1016/j.jconrel.2010.02.027
    - WALDHERR et al., "Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC", Journal of nuclear medicine, (20020000), vol. 43, no. 5, pages 610 - 6
    - BODEI et al., "Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours", Eur J Nucl Med Mol Imaging, (20040000), vol. 31, no. 7, pages 1038 - 46
    - VAN ESSEN et al., "Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours", Acta oncologica., (20070000), vol. 46, no. 6, pages 723 - 34
    - NORENBERG et al., "213Bi-[DOTAO, Tyr3]octreotide peptide receptor radionuclide therapy of pancreatic tumors in a preclinical animal model", Clinical cancer research, (20060000), vol. 12, no. 3, pages 897 - 903
    - IMHOF et al., "Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers", Journal of clinical oncology, (20110000), vol. 29, no. 17, pages 2416 - 23
    - ROLLEMAN et al., "Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine", Eur J Nucl Med Mol Imaging, (20030000), vol. 30, no. 1, pages 9 - 15
    - KUNIKOWSKA et al., "Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option?", Eur J Nucl Med Mol Imaging, (20110000), vol. 38, no. 10, doi:10.1007/s00259-011-1833-x, pages 1788 - 97, XP019949149

DOI:   http://dx.doi.org/10.1007/s00259-011-1833-x
    - CONROY et al., "Efficient use of the Dmab protecting group: applications for the solid-phase synthesis of A-linked glycopeptides", Organic & Biomolecular Chemistry, (20080000), vol. 7, no. 11, pages 2255 - 2258
    - GAGNON et al., "High-throughput in vivo screening of targeted molecular imaging agents", Proceedings of the National Academy of Sciences, (20090000), vol. 106, no. 42, pages 17904 - 17909
    - HAUSNER et al., "Targeted In vivo imaging of intergrin α β with an improved radiotracer and its relevance in a pancreatic tumor model", Cancer Research, (20090000), vol. 69, doi:10.1158/0008-5472.CAN-08-4410, page 5843, XP055231867

DOI:   http://dx.doi.org/10.1158/0008-5472.CAN-08-4410
    - HOSSEINIMEHR et al., "Liver uptake of radiolabeled targeting proteins and peptides: considerations for targeting peptide conjugated design", Drug Discovery Today, (20120000), vol. 17, no. 21-22, pages 1224 - 32
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.